388 related articles for article (PubMed ID: 31617173)
21. Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors.
Ozuer A; Wechuck JB; Russell B; Wolfe D; Goins WF; Glorioso JC; Ataai MM
Biotechnol Prog; 2002; 18(3):476-82. PubMed ID: 12052062
[TBL] [Abstract][Full Text] [Related]
22. In vivo transgene activation from an HSV-based gene therapy vector by GAL4:vp16.
Oligino T; Poliani PL; Marconi P; Bender MA; Schmidt MC; Fink DJ; Glorioso JC
Gene Ther; 1996 Oct; 3(10):892-9. PubMed ID: 8908503
[TBL] [Abstract][Full Text] [Related]
23. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
24. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
25. HSV as a vector in vaccine development and gene therapy.
Marconi P; Argnani R; Berto E; Epstein AL; Manservigi R
Hum Vaccin; 2008; 4(2):91-105. PubMed ID: 18496918
[TBL] [Abstract][Full Text] [Related]
26. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
[TBL] [Abstract][Full Text] [Related]
27. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Johnston KM; Jacoby D; Pechan PA; Fraefel C; Borghesani P; Schuback D; Dunn RJ; Smith FI; Breakefield XO
Hum Gene Ther; 1997 Feb; 8(3):359-70. PubMed ID: 9048203
[TBL] [Abstract][Full Text] [Related]
28. Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression.
Han F; Miyagawa Y; Verlengia G; Ingusci S; Soukupova M; Simonato M; Glorioso JC; Cohen JB
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950408
[TBL] [Abstract][Full Text] [Related]
29. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
30. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
[TBL] [Abstract][Full Text] [Related]
32. Herpes simplex virus type 1 (HSV-1)-derived amplicon vectors.
Melendez ME; Fraefel C; Epstein AL
Methods Mol Biol; 2014; 1144():81-98. PubMed ID: 24671678
[TBL] [Abstract][Full Text] [Related]
33. HSV-1 Amplicon Vectors as Genetic Vaccines.
Meier AF; Laimbacher AS
Methods Mol Biol; 2020; 2060():111-130. PubMed ID: 31617175
[TBL] [Abstract][Full Text] [Related]
34. Multiple applications for replication-defective herpes simplex virus vectors.
Burton EA; Wechuck JB; Wendell SK; Goins WF; Fink DJ; Glorioso JC
Stem Cells; 2001; 19(5):358-77. PubMed ID: 11553845
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
36. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
37. Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors.
Tsitoura E; Lucas M; Revol-Guyot V; Epstein AL; Manservigi R; Mavromara P
J Gen Virol; 2002 Mar; 83(Pt 3):561-566. PubMed ID: 11842251
[TBL] [Abstract][Full Text] [Related]
38. A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant.
Yao F; Eriksson E
Hum Gene Ther; 1999 Jul; 10(11):1811-8. PubMed ID: 10446921
[TBL] [Abstract][Full Text] [Related]
39. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
40. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]